Nancy Lurker - Interpace Diagnostics Insider

Interpace Diagnostics Group Inc -- Exotistan Stock  

USD 0.53  0.06  10.17%

CEO and President and Director

Ms. Nancy S. Lurker is President Chief Executive Officer Director of PDI Inc. Prior to joining PDI Ms. Lurker joined us as Chief Executive Officer and a director in November 2008. Prior to joining PDI Ms. Lurker was senior vicepresident and chief marketing officer for Novartis Pharmaceuticals Corporationrationration the U.S. subsidiary of Novartis AG where she oversaw a product portfolio in multiple therapeutic areas from 2006 to 2007. Prior to that she served as president and chief executive officer of ImpactRx Inc. from 2003 to 2006 a privately owned company offering among its services the evaluation of the impact of pharmaceutical promotion on the prescribing behavior of the nations highest prescribing physicians. From 2000 to 2003 Ms. Lurker served as group vice presidentglobal primary care products for Pharmacia Corporationrationration where she led a business unit that commercialized drugs for urology cardiovascular central nervous system respiratory and womens health. During her time at Pharmacia Ms. Lurker was also a member of Pharmacias U.S. executive management committee the group responsible for managing all U.S.based profits as well as all U.S. management policies. Prior to her employment at Pharmacia Ms. Lurker spent 14 years at BristolMyers Squibb. During her 14 years at BristolMyers Squibb Ms. Lurker rose from senior sales representative at Mead Johnson a subsidiary of BMS at the time to various product management and business development positions ultimately becoming senior directorworldwide cardiovascular franchise management. Ms. Lurker currently serves as a member of the board of directors of Mallinckrodt Pharmaceuticals plc since June 2013. Ms. Lurker was a member of the board of directors of Auxilium Pharmaceuticals Inc. from 2011 through January 2015 Elan Pharmaceuticals during 2005 and 2006 and of ConjuChem Biotechnologies Inc. from 2004 to 2006.
Age: 57  CEO Since 2015      
Lurker received a B.S. in Biology with high honors from Seattle Pacific University and an M.B.A. from the University of Evansville in Evansville, Indiana.

Nancy Lurker Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (15.11) % which means that it has lost $15.11 on every $100 spent on asset. This is way below average.
The company currently holds 27.91 M in liabilities with Debt to Equity (D/E) ratio of 4.76 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Diagnostics Group Inc has Current Ratio of 1.0 suggesting that it may have difficulties to pay its financial obligations when they are due.

Entity Summary

PDI, Inc. offer outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. Interpace Diagnostics Group Inc (PDII) is traded on Commodity Exchange in Exotistan. It is located in PDI, Inc.Parsippany, NJ and employs 775 people.

Did you try this?

Run Portfolio Volatility Now

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
Hide  View All  NextLaunch Portfolio Volatility
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Interpace Diagnostics Group Inc to your portfolio

Top Management

Interpace Diagnostics Leadership Team
Stephen Sullivan, Director, MBA
Graham Miao, President
Kapila Ratnam, Director
Nancy Lurker, CEO
Jennifer Leonard, SVP
Veronica Lubatkin, Director
Gerald Melillo, Executive
Heiner Dreismann, Director
Jack Stover, Director
Frank Arena, SVP
Asher Dewhurst, Executive
John Federspiel, Director, MBA
Gerald Belle, Chairman, MBA

Stock Performance

Interpace Diagnostics Performance Indicators